Loading patent…
AssigneeBristol-Myers Squibb Company
InventorsLi-Sheng Lu, Mark J. Selby, Alan J. Korman, Shrikant Deshpande, Mohan Srinivasan, Jun Zhang, Haichun Huang, Guodong Chen, Richard Y. Huang, Ekaterina Deyanova
Estimating the term…
This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.
An agonist monoclonal antibody or an antigen-binding portion thereof that specifically binds to human CD27, wherein the antibody or portion thereof comprises:
An agonist monoclonal antibody that specifically binds to human CD27 and does not block binding to its CD70 ligand, wherein the monoclonal antibody is the monoclonal antibody designated BMS-986215, which comprises a heavy chain comprising consecutively linked amino acids having the sequence set forth as SEQ ID NO:
Dependencies are inferred from the claim text.